Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of MB0151 in adults with advanced somatostatin receptor-expressing solid tumors
CTR20250231Phase 2Active
- Sponsor
- Mainline Biosciences
- Start
- May 2025
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MB0151 in Nonhematologic neoplasms, small cell lung cancer (SCLC), Gastroenteropancreatic Carcinoid Tumor, triple-negative breast cancer (TNBC), sponsored by Mainline Biosciences. Started May 2025; status: active.
02
Drugs
MB0151
03
Conditions
Nonhematologic neoplasmssmall cell lung cancer (SCLC)Gastroenteropancreatic Carcinoid Tumortriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20250231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250231.